NASDAQ$ENGN
enGene Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
enGene reported financial results for Q1 2024 and provided a corporate progress update.
enGene reported a net loss attributable to common shareholders of $10.7 million, or $0.46 per share, for the three months ended January 31, 2024. The company's cash and cash equivalents were $85.6 million as of January 31, 2024, and with the recent private placement, expects to fund operations into 2027.
- Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive NMIBC remains on track with interim data anticipated in mid-2024.
- Closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027.
- Total operating expenses were $10.8 million for the three months ended January 31, 2024.
- Net loss attributable to common shareholders was $10.7 million, or $0.46 per share for the three months ended January 31, 2024.
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
enGene anticipates several milestones and corporate updates.
Tailwinds
- Announce a new indication and development plans for EG-70 in the first half of 2024.
- Interim data readout from the ongoing pivotal Phase 2 LEGEND study of EG-70 in BCG-unresponsive NMIBC with carcinoma-in-situ (Cis) in mid-2024.
- Initial efficacy data from the ongoing Phase 2 LEGEND study in a BCG-naive NMIBC cohort in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2024
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro